AstraZeneca (LON:AZN) Stock Rating Reaffirmed by Morgan Stanley

AstraZeneca (LON:AZNGet Rating)‘s stock had its “overweight” rating reissued by research analysts at Morgan Stanley in a research note issued on Wednesday, reports.

AZN has been the subject of several other research reports. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a £115 ($141.78) target price on shares of AstraZeneca in a research report on Wednesday. UBS Group set a £105 ($129.45) target price on AstraZeneca in a research report on Monday, March 7th. Jefferies Financial Group set a GBX 9,500 ($117.12) target price on AstraZeneca in a research report on Friday, April 29th. Credit Suisse Group set a £110 ($135.62) target price on AstraZeneca in a research report on Tuesday, May 3rd. Finally, Deutsche Bank Rese… set a £115 ($141.78) target price on AstraZeneca in a research report on Tuesday, May 3rd. One research analyst has rated the stock with a sell rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of £104.75 ($129.14).

AZN opened at £100.99 ($124.51) on Wednesday. The firm has a market cap of £156.48 billion and a PE ratio of 1,606.03. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 90.06. The business has a fifty day simple moving average of £100.31 and a 200-day simple moving average of GBX 9,144.10. AstraZeneca has a fifty-two week low of GBX 7,642 ($94.22) and a fifty-two week high of £110 ($135.62).

About AstraZeneca (Get Rating)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Featured Stories

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.